Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Arqit Quantum Inc (ARQQ) Price & Performance

Abeona Therapeutics IncTrade
Arqit Quantum IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Arqit Quantum Inc — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Arqit Quantum Inc trades at $23.4 (market cap $424.79M). The key difference: Abeona Therapeutics Inc and Arqit Quantum Inc are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.

ABEOARQQ
Market Cap
$421.19M$424.79M
Sector
HealthTechnology
52-Week High
$7.45$58.27
52-Week Low
$4.17$11.78
Enterprise Value
$276.10M$398.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Arqit Quantum Inc

ARQQ trades at $24.10, up 6.59% today, with a bullish technical signal from moving averages. The company shows explosive revenue growth (829% YoY in H1 2026) but remains deeply unprofitable with a -4,508% net margin. Recent news highlights quantum-safe encryption partnerships with telecom and government clients, driving investor optimism despite significant financial losses.

Outlook remains speculative with high risk/reward profile. The quantum security market offers substantial growth potential, but ARQQ must demonstrate path to profitability amid heavy operating losses. Analyst consensus is divided (50% Buy, 50% Hold), reflecting uncertainty about timeline for sustainable operations.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Arqit Quantum Inc

Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.

Read more on ARQQ